FDA Limits Duchenne Gene Therapy After Two Teens Die of Liver Failure
MONDAY, Nov. 17, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) is tightening restrictions on a gene therapy used to treat Duchenne muscular dystrophy after two teenagers died from liver failure linked to the medication. The FDA decision limits the use of Elevidys, made by Sarepta Therapeutics,Continue Reading










